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Abstract Classical homocystinuria is due to cystathio-
nine b-synthase (CBS) deﬁciency. More than 130
mutations, which diﬀer in prevalence and severity, have
been described at the CBS gene. Mutation p.I278T is
very prevalent, has been found in all European countries
where it has been looked for with the exception of the
Iberian peninsula, and is known to respond to vitamin
B6. On the other hand, mutation p.T191M is prevalent
in Spain and Portugal and does not respond to B6. We
analysed 30 pedigrees from Spain, Portugal, Colombia
and Argentina, segregating for homocystinuria. The
p.T191M mutation was detected in patients from all
four countries and was particularly prevalent in
Colombia. The number of p.T191M alleles described in
this study, together with those previously published, is
71. The prevalence of p.T191M among CBS mutant
alleles in the diﬀerent countries was: 0.75 in Colombia,
0.52 in Spain, 0.33 in Portugal, 0.25 in Venezuela, 0.20 in
Argentina and 0.14 in Brazil. Haplotype analyses
suggested a double origin for this mutation. No geno-
type–phenotype correlation other than the B6-nonre-
sponsiveness could be established for the p.T191M
mutation. Additionally, three new mutations, p.M173V,
p.I429del and c.69_70+8del10, were found. The
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p.M173V was associated with a mild, B6-responsive,
phenotype.
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Introduction
Homocystinuria due to cystathionine b-synthase (CBS)
deﬁciency (MIM +236,200) is the most common in-
born error of methionine metabolism. The worldwide
incidence for this disease is highly variable and has
been reported at 1 in 344,000 (Mudd et al. 1995),
compared to a much higher incidence in Ireland of 1 in
65,000 (Naughten et al. 1998). However, estimates
based on DNA screening of newborns are much higher:
1:6,000 (Refsum et al. 2004). CBS is a pyridoxal 5-
phosphate (PLP)-dependent enzyme that condenses
homocysteine and serine to form cystathionine, an
irreversible step in the transsulfuration pathway (Mudd
et al. 1995).
The ﬁrst homocystinuric patient was described by
Carson and Neill (1962) among mentally retarded indi-
viduals and, 2 years later, it was shown that the primary
deﬁciency in homocystinuria was an enzymatic defect of
CBS (Mudd et al. 1964) with an autosomal recessive
mode of inheritance (Finkelstein et al. 1964). At the
clinical level, symptoms are highly variable, aﬀecting the
eye, the skeleton, the vascular system and the central
nervous system (CNS). Usually, these include ectopia
lentis, osteoporosis, scoliosis, Marfanoid features, pre-
mature arteriosclerosis, thromboembolism and mental
retardation. Biochemically, patients with CBS deﬁciency
are characterized by severe hyperhomocysteinemia and
homocystinuria, hypermethioninemia, and decreased
plasma cysteine levels.
The human CBS gene, which has been mapped to
21q22.3 (Munke et al. 1988), encodes a CBS polypeptide
of 63 kDa, which forms homotetramers (Kraus et al.
1978), binds heme and PLP, and is regulated by S-
adenosylmethionine. More than 130 mutations have
been detected in the CBS gene (Kraus 1998), and func-
tional relevance has been tested for some of them in
either bacterial (Kozich and Kraus 1992; de Franchis
et al. 1994; Marble et al. 1994; Kluijtmans et al. 1996,
among others) or a yeast (Kruger and Cox 1995)
expression systems.
Although most mutations seem to be unique or re-
stricted to only a few pedigrees, in some populations one
mutation is relatively common. A c.833T>C transition
(p.I278T) (Kozich and Kraus 1992) has been found in
nearly 25% of all homocystinuric alleles from patients of
diﬀerent ethnic backgrounds. This common mutation
has been reported to be generally associated with pyri-
doxine responsiveness and a relatively mild clinical
phenotype when present in the homozygous state (Shih
et al. 1995). On the other hand, a c.919G>A transition
(p.G307S) is related to a more severe clinical phenotype
and has been detected mainly in alleles from homocys-
tinuric patients of Celtic origin, representing nearly 70%
of the homocystinuric alleles in Ireland (Gallagher et al.
1995). We previously reported the third most prevalent
mutation, a c.572C>T transition (p.T191M), which is
very common in the Iberian Peninsula, representing
50% of all Spanish homocystinuric alleles (Urreizti et al.
2003). Patients homozygous for the p.T191M mutation
were found to be B6-nonresponders. Recently, this
mutation was also described in Venezuela (De Lucca
and Casique 2004).
Therapy in CBS-deﬁcient patients usually consists of
the administration of high doses of pyridoxine (vitamin
B6), the precursor of PLP. Nearly 50% of 1,600 patients
with homocystinuria worldwide responded to pharma-
cological doses of pyridoxine with a substantial reduc-
tion in blood homocysteine concentrations (Mudd et al.
1985). Pyridoxine-nonresponsive patients are usually
more severely aﬀected than pyridoxine-responsive pa-
tients and, for the former, treatment consists usually of
combinations of folic acid, hydroxycobalamin, and
betaine to stimulate remethylation of homocysteine to
methionine.
In this study, we analysed the presence of the
p.T191M mutation in 35 homocystinuric patients from
Spain, Colombia, Argentina and Portugal. Our data,
together with those from previous studies, reveal the
high frequency of this change both in the Iberian Pen-
insula and in several South American countries.
Materials and methods
Patients
This study involved 35 patients with homocystinuria due
to CBS deﬁciency from 30 unrelated pedigrees of diﬀer-
ent geographical origins, including ﬁve sib-pairs. Sixteen
of the families were from Spain, eight from Colombia,
ﬁve from Argentina and one from Portugal. Patients
were initially diagnosed on the basis of clinical manifes-
tations suggestive of homozygous CBS deﬁciency, in
combination with severe hyperhomocysteinaemia (typi-
cally above 150 lmol/l), severe hypermethioninaemia
(typically above 40 lmol/l) and, in most cases, deﬁcient
CBS activity in cultured ﬁbroblasts. Exceptionally, pa-
tient #63 was identiﬁed through a neonatal screening
program. Enzyme activity was measured either in the
laboratory of H.J. Blom (Nijmegen, The Netherlands),
or in that of Dr. Rolland (Lyon, France). Clinical and
biochemical data were provided by the patients’ physi-
cians. Disease severity and B6 responsiveness were as-
sessed by each physician according to the criteria
described in Kraus et al. (1999). Our research was con-
ducted in accordance with the tenets of the Declaration
of Helsinki. The nature and possible consequences of the
study were ﬁrst explained to all patients and/or their
parents, before their informed consent for inclusion in
the research project was obtained.
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DNA preparation
Genomic DNA was prepared from peripheral blood
leukocytes, using a Wizard Genomic DNA puriﬁcation
Kit (Promega, Madison, WI).
Genotyping of mutation p.T191M
and of the polymorphisms
Mutation p.T191M was typed by PCR ampliﬁcation of
exon 5 using a mismatched primer followed by digestion
with the restriction enzyme Hsp92II. Primer sequences
and PCR conditions are shown in Table 1. Analysis of
the CBS 844ins68 polymorphism was carried out using
primers CBS_8F and CBS_8R (Table 1) to yield a
product of 596 bp (if wild-type) and of 664 bp (if the
insertion was present). The analyses of the polymor-
phisms c.699C >T and c.1080C >T of CBS and
c.677C>T of MTHFR, as well as the STR D21S1411
(GenBank L17803), were performed as previously de-
scribed (Urreizti et al. 2003).
Scanning for unknown mutations of the CBS gene
A new collection of 13 primer pairs was designed to am-
plify the entire CBS coding exons together with intronic
ﬂanking sequences under three PCR programs (Table 1).
PCR reactions were performed in a volume of 50 ll
containing 100 ng genomic DNA, 0.7 U Taq DNA
polymerase (Promega, Wisconsin, MI) in the buﬀer
supplied (including 1.5, 2 or 2.5 mMMgCl2), 0.4 mM of
each primer and 0.2 mM of each dNTP. The three PCR
programs included a ﬁrst denaturing step of 2 min at
95C, followed by 35 cycles of 95C for 30 s, an annealing
step at 57, 59 or 65C (Table 1) for 20 s, and an extension
step at 72C for 20 s. A ﬁnal step of 5 min at 72C was
included in all three programs. PCR products were
puriﬁed by GFX PCR DNA and Gel Band Puriﬁcation
Kit (Amersham Pharmacia Biotech, Piscataway, NJ).
Subsequently, sequence reactions were performed using
BigDyeTerminatorCycle Sequencing v3.1, (ABIPRISM,
Applied Biosystems, Foster City, CA). All mutations
detectedwere conﬁrmedby digestion of the PCRproducts
with the appropriate restriction enzyme, and 50 control
samples were analysed for all new mutations.
Haplotype analysis and linkage disequilibrium
measurements
Haplotypes for the CBS single nucleotide polymor-
phisms (SNPs) c.699C >T and c.1080C >T were
estimated from the genotypic data on 113 control
individuals using PHASE (version 2.1.1) (Stephens
et al. 2001). Linkage disequilibrium (LD) signiﬁcance
values were obtained by the Chi-square test.
Table 1 Primers used for cystathionine b-synthase gene (CBS) ampliﬁcation
Name Exons Primers Fragment
size
Annealling
temperature
(C)
[Mg2+]
(mM)
T191M-Fa 5 CACTGGGGGCTGAGATTGTGAGCA 152 59 2.5
T191M-R GGAATGCCTGTCTCCAGGCCCC
CBS_1F 1 GGAACCCCACAGCATCCGAG 302 59 2.5
CBS_1R TCAGCCCTCTTGTGATCAAAAGC
CBS_2F 2 TTTCCAGTTCTTCGAGTGTTG 346 57 2
CBS_2R GGCCACTCATTAACCAGCGA
CBS_3F 3 TTTTCAGAACCCACAGACC 438 65 1.5
CBS_3R TCAAAGGAAGCTAGGTTGG
CBS_4F 4–6 GGCCCCTCTCACCCTCTG 626 59 1.5
CBS_6R GGTTCTGAAGGGTGAATAGG
CBS_7F 7 ACTTTTTGGTTACCCACCG 342 57 2.5
CBS_7R CCTTGTCTTCCCAAACACC
CBS_8F 8 CTGAACATTTAGGTCATTACC 598 57 2.5
CBS_8R TTTCACACGTTTTCCCTGC
CBS_9F 9 TGTCTGCAAAACGTGTTGG 527 59 2
CBS_9Rn AGCTTCAGCCTTGTTCTAG
CBS_10F 10 CATGCTCCCATGCGTGCACGTGC 244 59 1.5
CBS_10R GCAGGATGGAGAGGAGCAGGG
CBS_11F 11–12 CAGTGAGGTCCAGGAGAG 617 59 1.5
CBS_12R AGACAGAACCCAGGACTG
CBS_13F 13 CGCTGACCCCTGCCTGCCC 190 65 1.5
CBS_13R GCCTGTAGGTGACTGCGCATC
CBS_14F 14 ACTCCACAGAAAACTCGTG 293 57 2
CBS_14R TAAAGACTGGGTGTCACTG
CBS_15F 15 CAAGTCTAACCCCATCTCC 217 57 2.5
CBS_15R AAGTAAATGTGAGATTAAGAGG
CBS_16F 16 AAAAAAAAAAAGGAACACAGCC 323 57 2
CBS_16R GAAAGCGAAGGAGAAGTGG
aMismatched primer
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Results
p.T191M frequencies in the Iberian Peninsula
and South America
The p.T191M mutation was typed in 35 homocystinuric
patients from 30 unrelated pedigrees. The results are
summarised in Table 2. Sixteen independent patients
(and four sibs) were homozygous for the change, four
patients were heterozygous, while the remaining ten did
not carry this mutation. For an estimate of the fre-
quency of p.T191M in diﬀerent countries, these data
were combined with those on genotypes of homocys-
tinuric patients of the same geographic areas found in
the literature (Table 2). In total, out of 156 alleles, 71
bore the p.T191M change. By country, the highest fre-
quency was found in Colombia (75% of the CBSmutant
alleles), followed by Spain (52%). In Argentina, only
one homozygous T191M patient was found (20%).
Haplotype associated with p.T191M
To analyse the haplotypes associated with the p.T191M
mutation, two internal polymorphisms (c.699C >T and
c.1080C >T) and the microsatellite D21S1411, located
312.6 kb centromeric to the CBS gene, were typed in
patients bearing the mutation. For this analysis, patients
described in Urreizti et al. (2003) and M. Bermudez et al.
(2006) were included, making a total of 66 p.T191M
alleles.
For the internal markers, phases could be estab-
lished in 56 of the chromosomes (Table 3). Two dif-
ferent haplotypes, named I and II, were associated
with the mutation. Neither of them carried the
c.844ins68 variant (not shown). Haplotype I was
present in 51/56 (0.91) p.T191M chromosomes. The
frequency of haplotype I among Spanish p.T191M
chromosomes was up to 0.96 (24/25) and among
Colombian chromosomes was 100% (25/25). In order
to calculate the LD between this haplotype and the
mutation, the population frequency of haplotype I was
established in 226 control chromosomes from Spain
and was found to be 0.35 (Table 3). LD between the
mutation and haplotype I was highly signiﬁcant
(P=4.2·107).
Microsatellite D21S1411 was typed in 36 of the
p.T191M bearing chromosomes (Table 3). The three
alleles more commonly encountered were 299 (prevalent
in Spanish p.T191M chromosomes), 303 (prevalent in
Colombian p.T191M chromosomes) and 307 (prevalent
in Portuguese p.T191M chromosomes). The analysis of
this marker in 114 control chromosomes from Spain
revealed that none of these alleles is frequent in the
general population of this country (Fig. 1). LD between
the mutation and the 299 allele of D21S1411 in the
Spanish population was also highly signiﬁcant
(P=9.7·108).
Table 2 Frequencies of the
T191M mutation in the Iberian
Peninsula and in four Latin-
American countries
aPatient #34, with genotype [T-
191M;D444N]/[T191M;D444N]
included
Patients by T191M genotype Total number
of patients
Allelic
frequency
T191M/T191M T191M/other Other/other
Colombia
This study 6 1 1 8
M. Bermudez et al. (2006) 7 0 3 10
Total 13 1 4 18 0.75
Spain
This study 8a 3 5 16
Sperandeo et al. (1995) 0 0 1 1
Urreizti et al. (2003) 5 2 6 13
Total 13 5 12 30 0.52
Portugal
This study 1 0 0 1
Coude´ et al. (1998) 0 0 1 1
Castro et al. (2001) 0 0 3 3
Gaustadnes et al. (2002) 0 0 1 1
Urreizti et al. (2003) 2 0 1 3
De Lucca (2004) 0 0 1 1
Total 3 0 7 10 0.30
Venezuela
De Lucca (2004) 1 0 3 4 0.25
Argentina
This study 1 0 4 5 0.20
Brazil
Porto et al. (2005) 1 1 9 11 0.14
All
This study 16 4 10 30
Other studies 16 3 29 48
Total 32 7 39 78
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CBS mutant alleles other than p.T191M found
in homocystinuric patients
To fully establish the CBS genotypes of the homocys-
tinuric patients, the entire CBS coding region plus
ﬂanking sequences was scanned for mutations in all
patients, including those previously found to be
homozygous for the p.T191M mutation. The 24 alleles
that remained unidentiﬁed were characterised, and were
found to bear 14 diﬀerent mutations, three of which
were novel (Table 4). Additionally, patient #34, previ-
ously shown to be a p.T191M homozygote, was found
to bear a second mutation, p.D444N, also in homo-
zygosis.
Genotype–phenotype correlations
A wide variety of phenotypes, involving the skeleton, the
eye and the CNS, was present among the 20 p.T191M
homozygotes. The phenotypic features of some of these
patients have been described previously (Urreizti et al.
2003). The lack of response to treatment with vitamin B6
was the only feature present in all of these patients.
Vascular disease was present in only two patients. Phe-
notypic characteristics of the four sib-pairs with this
genotype are listed in Table 5. Two of the pairs were
discordant for several of the features.
Phenotypic characteristics of patients bearing other
genotypes are listed in Table 4. Three patients, #22
(pA226T/p.A226T), #38 (p.A114V/p.I429del) and #28
(p.M173V/p.T191M), were responsive to vitamin B6
treatment. A marfanoid habitus, lens subluxation and
skeletal anomalies were general among the patients,
while vascular disease or CNS involvement were vari-
able. The sib-pair 30a–30b was discordant for most of
the traits. In patient #54 (p.D444N/ p.D444N), the main
feature was a premature cerebral thrombosis. Patient
#63 was diagnosed through a neonatal screening pro-
gram. Her plasma total homocysteine value at diagnosis
was 148.12 lmol/l, and after 6 months of treatment with
pyridoxine (100 mg·2), cystine (400 mg·1) and a
methionine-free diet it dropped to <20 lmol/l.
Discussion
In this study, 35 homocystinuric patients from Spain,
Colombia, Argentina and Portugal were genotyped for
the p.T191M mutation of CBS; the mutation was de-
tected in all four countries, illustrating its wide geo-
graphic distribution from South-Western Europe to
Table 3 Haplotypes associated with the p.T191M mutation in diﬀerent populations
699C >T 1080C > T Number
of alleles
Frequency D21S1411a Number
of alleles
Spain Portugal Colombia
56 chromosomes bearing p.T191M
Haplotype I C T 51 0.91 Allele 299 16 13 2 1
Allele 303 8 1 0 7
Other allele 7 7 0 0
NDb 20 3 0 17
Haplotype II T C 5 0.09 Allele 307 5 1 4 0
226 Spanish wild-type chromosomes
Haplotype I C T 78 0.35
Haplotype II T C 71 0.31
Haplotype III C C 71 0.31
Haplotype IV T T 6 0.03
aGenBank L17803
bNot determined
0,00
0,05
0,10
0,15
0,20
0,25
0,30
0,35
0,40
0,45
0,50
259 267 271 275 279 283 287 291 295 299 303 307 311 315 319
Fig. 1 Distribution of alleles
(relative frequencies) of the
D21S1411 STR (GenBank
L17803) among 114 Spanish
control chromosomes (white)
and 25 Spanish chromosomes
bearing the p.T191M mutation
(gray). Allele names (numbers
in the X-axis) correspond to the
sizes of the PCR products
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South America. Recently, the mutation was also re-
ported in two other Latin American countries, namely
Venezuela (De Lucca and Casique 2004) and Brazil
(Porto et al. 2005). The highest prevalence was found in
Colombia. In two diﬀerent groups of patients, gathered
in Medellı´n (this study) or Bogota´ (M. Bermudez et al.
2006) the p.T191M homozygous genotype was above
70%. A homozygous patient was also detected among
ﬁve Argentinian patients. This is the ﬁrst mutation re-
port on homocystinuric patients from Argentina.
The ﬁnding of the mutation associated with two dif-
ferent CBS haplotypes strongly suggests a double origin
for the p.T191M mutation. While haplotype I was the
most frequently encountered in the Spanish and
Colombian chromosomes, haplotype II was found in 4/6
Portuguese chromosomes and in a Spanish chromo-
some. The mutation associated with haplotype I might
have arisen in Spain and travelled to Colombia where it
expanded. Both historical data and the limited infor-
mation on the external STR D21S1411 would support
this hypothesis.
The high prevalence of p.T191M makes the study of
genotype–phenotype correlations an important issue. A
wide spectrum of phenotypes, ranging from mild to se-
vere, were observed. This highlights the relevant roles
played by the genetic background and, probably more
importantly, by nongenetic factors such as age at diag-
nosis, treatment and diet. The main common features
for the p.T191M homozygotes seem to be the low
prevalence of vascular disease and the lack of response
to B6 treatment. Because pyridoxine does not help these
patients, additional treatments should be conducted. In
this regard, some patients treated with betaine displayed
a signiﬁcant reduction of total plasma homocysteine.
The p.T191M mutation was expressed heterologously in
Escherichia coli and the resulting protein displayed nei-
ther detectable enzyme activity nor response to PLP
(Urreizti et al. 2006).
Three new mutations were identiﬁed among the pa-
tients: p.M173V, p.I429del and c.69_70+8del10. The
p.M173V change was present in compound heterozy-
gosis with p.T191M in a Spanish homocystinuric patient
(#28) whose phenotype was rather mild, and responsive
to B6. This mutation was also expressed in E. coli
(Urreizti et al. 2006). In agreement with the mild pa-
tient’s phenotype, the resulting protein retained 40% of
the wild-type enzyme activity, and displayed a moderate
response to PLP. The p.I429del mutation was present, in
compound heterozygosis with p.A114V, in an Argen-
tinean patient (#38) presenting a mild phenotype and a
positive response to B6. The fact that the accompanying
mutation is known to be associated with a mild pheno-
type (Kozich et al. 1993; de Franchis et al. 1999) pre-
cludes our drawing conclusions on the eﬀects of
p.I429del. Regarding the third novel mutation identiﬁed,
c.69_70+8del10, the fact that the 10-bp deletion in-
cluded the donor site of intron 1 supports a pathogenic
role for this change. According to reports on another
mutation, IVS1+1G>A (g.210G>A, Gordon et al.T
a
b
le
5
P
h
en
o
ty
p
ic
fe
a
tu
re
s
in
si
b
-p
a
ir
s
b
ea
ri
n
g
th
e
p
.T
1
9
1
M
/p
.T
1
9
1
M
g
en
o
ty
p
e.
P
y
r
P
y
ri
d
o
x
in
e,
B
et
b
et
a
in
e,
F
A
fo
li
c
a
ci
d
,
M
F
D
m
et
h
io
n
in
e-
fr
ee
d
ie
t
P
a
te
n
t
n
u
m
b
er
A
g
e
a
t
d
ia
g
n
o
si
s
D
a
te
d
ia
g
n
o
si
s
(m
o
n
th
/y
ea
r)
G
en
o
ty
p
e
M
T
H
F
R
c.
6
7
7
C
>
T
O
ri
g
in
C
li
n
ic
a
l
m
a
n
if
es
ta
ti
o
n
E
y
e
S
k
el
et
o
n
V
a
sc
u
la
r
sy
st
em
C
N
S
M
a
rf
a
n
o
id
fe
a
tu
re
s
M
et
a
T
re
a
tm
en
t
B
6
re
sp
o
n
si
v
e
S
ev
er
it
y
2
1
a
1
0
y
ea
rs
1
0
/9
8
p
.T
1
9
1
M
/p
.T
1
9
1
M
C
/C
P
o
rt
u
g
a
l
+


+
Y
es
5
2
9
P
y
r.
B
et
.b
N
D
c
S
ev
er
e
2
1
b
1
3
y
ea
rs
1
2
/9
8
p
.T
1
9
1
M
/p
.T
1
9
1
M
C
/C
P
o
rt
u
g
a
l
+



N
o
6
1
n
o
N
D
M
il
d
3
3
a
6
y
ea
rs
0
2
/9
0
p
.T
1
9
1
M
/p
.T
1
9
1
M
C
/T
S
p
a
in
+
+


Y
es
1
1
2
P
y
r.
F
A
B
et
.M
F
D
N
o
M
o
d
er
a
te
3
3
b
3
y
ea
rs
0
5
/9
0
p
.T
1
9
1
M
/p
.T
1
9
1
M
C
/T
S
p
a
in




N
o
2
6
3
P
y
r.
F
A
B
et
.M
F
D
N
o
M
il
d
4
1
a
6
y
ea
rs
1
2
/9
4
p
.T
1
9
1
M
/p
.T
1
9
1
M
C
/T
S
p
a
in
+
+

+
Y
es
1
8
8
P
y
r.
F
A
N
o
S
ev
er
e
4
1
b
1
9
y
ea
rs
0
2
/9
5
p
.T
1
9
1
M
/p
.T
1
9
1
M
C
/T
S
p
a
in
+
+

+
Y
es
2
3
9
P
y
r.
F
A
N
D
S
ev
er
e
5
3
a
–
–
p
.T
1
9
1
M
/p
.T
1
9
1
M
C
/T
C
o
lo
m
b
ia
+
+

+
Y
es
–
–
N
o
S
ev
er
e
5
3
b
–
–
p
.T
1
9
1
M
/p
.T
1
9
1
M
C
/T
C
o
lo
m
b
ia
+
+

+
Y
es
–
–
N
o
S
ev
er
e
a
M
et
h
io
n
in
e
a
t
d
ia
g
n
o
si
s
(l
M
)
b
T
re
a
tm
en
t
st
a
rt
ed
a
t
a
g
e
1
2
y
ea
rs
c N
o
t
d
et
er
m
in
ed
311
1998), in which the intron 1 splicing donor site was also
aﬀected, the probable consequences of this mutation are
the deletion of exon 1 or a deletion of 157 bp starting at
position c.153.
Patient #54 was homozygous for mutation p.D444N,
and presented with a phenotype characterised by vascu-
lar involvement as the main feature, together with a
Marfanoid habitus. This mutation lies in the C-terminal
domain, where Maclean et al. (2002) described several
patient-derived CBS mutations, including p.D444N,
associated with a phenotype characterised by vascular
involvement as the only feature. The ﬁrst patient de-
scribed with the p.D444N/p.D444N mutation (Kluijt-
mans et al. 1996) presented with a more complex
phenotype, including psychomotor retardation and
marfanoid features such as excessive height, dolichoste-
nomelia, and arachnodactyly. It should be noted that
two patients in our series bore p.D444N: patient #54
(described above) and patient #34. The latter was
homozygous for the double-mutant allele p.[T191M;
D444N]. Both patients originate from the same region of
Spain.
Finally, it is also worth mentioning the potential
usefulness of the neonatal screening program based on
tandem-mass spectrometry, which allowed the identiﬁ-
cation of a homocystinuric patient and the immediate
start of treatment. The follow-up of this patient will
establish whether this early start is an eﬃcient way to
avoid the manifestation of clinical symptoms.
In summary, we have shown that the p.T191M
mutation, previously reported as a prevalent CBS
mutation in Spain and Portugal, is also highly prevalent
in Latin American countries. Haplotype analyses sug-
gest that the mutant allele had two independent origins.
The lack of response to vitamin B6 treatment is the main
common phenotypic feature associated with this muta-
tion.
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